Pharmaceuticals, Biotechnology and Life Sciences
Mr. Lynch Brings Extensive Strategic, Operational and Leadership Experience in Biotechnology WALTHAM, Mass.–(BUSINESS WIRE)–Xilio Therapeutics, a company developing potent, tumor-selective…
DUBLIN–(BUSINESS WIRE)–The “U.S. National Biotechnology Database – Premium Subscription” newsletter from Rich’s Business Information has been added to ResearchAndMarkets.com’s offering.…
ISTURISA® (osilodrostat) demonstrates significant and sustained benefit over placebo at normalizing mean urinary free cortisol (mUFC) levels in patients with…
IL-11 is key mediator of fibrosis and the tumor microenvironment Leadership team has collectively brought more than twenty antibody therapeutics…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved FoundationOne®CDx as a companion…
KEYTRUDA Is Now Approved for Adult and Pediatric Patients with Unresectable or Metastatic Tumor Mutational Burden-High (TMB-H) [≥10 Mutations/Megabase] Solid…
KENILWORTH, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside the United States and Canada, yesterday priced a $4.5 billion…
With novel drug development platform in place, the company deepens pharmaceutical industry expertise and connections BOSTON–(BUSINESS WIRE)–Dewpoint Therapeutics, the biomolecular…
Actinium Pharmaceuticals on Wednesday announced the pricing of its previously announced public offering with gross proceeds expected to be approximately $25.0 million.
ISTURISA® (osilodrostat) demonstrates significant and sustained benefit over placebo at normalizing mean urinary free cortisol (mUFC) levels in patients with…